ADORA3 and central nervous system cancer: Compound 44 was subsequently tested on human glioma U87MG cells, and it was able to counteract the proliferation of glioma cells mediated by A3 AR agonists Cl-IB-MECA and IB-MECA through the inhibition of A3 AR agonist-mediated ERK 1/2 activation.